BRAF and melanoma: All the OCAv3-detected RET and NTRK fusions detected in tumors that were pre-screened with the successively clinically available MassARRAY® tests, BRAF test, Colon Panel, and Melanoma Panel test, are covered by the ThyroSPEC assay and were subsequently confirmed with the clinically validated ThyroSPEC assay after their detection by OCAv3 analysis.